Lead Product(s) : Fluconazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lupin Gets USFDA Nod to Market Generic Antifungal Tablets
Details : Fluconazole, the first of a new subclass of synthetic triazole antifungal agents, is available as tablets for oral administration, which is indicated for the treatment of Vaginal candidiasis.
Product Name : Diflucan-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 25, 2023
Lead Product(s) : Fluconazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fluconazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : $3.0 million
Deal Type : Acquisition
ANI Pharmaceuticals Announces Acquisition of Fluconazole Tablets
Details : ANI Pharmaceuticals acquired Fluconazole Tablets USP, 50mg, 100mg, 150mg, and 200mg. Fluconazole Tablets USP is indicated for the treatment of vaginal candidiasis (vaginal yeast infections due to Candida) and oropharyngeal and esophageal candidiasis.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 07, 2020
Lead Product(s) : Fluconazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : $3.0 million
Deal Type : Acquisition
Reset All
